Pay in 4 interest-free payments of $7.43 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
The 2-year cap is a cost-effectiveness recommendation based on the duration of trial evidence available at the time of the appraisal
For example, semaglutide GLP-1 may be more effective than liraglutide in reducing blood sugar and promoting weight loss, but also noting that it may present a higher risk of gastrointestinal side effects
The Medicare GLP-1 Bridge Program lets eligible Medicare Part D beneficiaries get Wegovy, Zepbound, or Foundayo for a $50 per month medication copay from July 1, 2026 through December 31, 2027
The main index comparison result of the product of the invention and the commercial product (1) Related substances Sample preparation: pilot samples (production lot: P-110201), process verification samples (production lot: YJ110401, YJ110402, and YJ110403), and commercial products (production lot: 31002)
US$ 24.08
US$ 28.29
US$ 24.25
US$ 21.34
US$ 23.37
US$ 19.99
US$ 24.48
US$ 27.51
US$ 21.20
US$ 28.94
